Peptide profile
Semaglutide (Liver Health)
GLP-1 agonist for non-alcoholic fatty liver disease
Compare Semaglutide (Liver Health) with other peptides →Summary
GLP-1 agonist for fatty liver & metabolic health.
- Typical dose
- 0.25-1.0mg (titrate) Once weekly
- Route
- Subcutaneous
- Cycle length
- Ongoing
- Evidence
- Limited human data
Mechanism
How it works
Semaglutide acts like a liver fat vacuum — it sucks fat out of liver cells by improving how your body processes sugar and fat.
Semaglutide reduces liver fat by suppressing appetite, improving insulin sensitivity, and directly reducing de novo lipogenesis in hepatocytes.
Reported in research
Benefits
- Reduces hepatic steatosis (fatty liver)
- Improves liver enzymes (ALT, AST)
- Slows progression of NASH
- Reduces liver fibrosis markers
Context, not a prescription
Dosing
- Typical range
- 0.25-1.0mg (titrate) Once weekly (Subcutaneous)
- Cycle length
- Ongoing
Safety
Side effects & contraindications
Possible side effects
- Nausea
- Vomiting
- Diarrhea
- Pancreatitis
- Gallstones
Contraindications
- Medullary thyroid carcinoma history
- MEN-2
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Reduced liver fat, improved liver enzymes, less inflammation.
How it works
Semaglutide acts like a liver fat vacuum — it sucks fat out of liver cells by improving how your body processes sugar and fat.
Activates GLP-1 receptors on hepatocytes, reducing lipogenesis and increasing fatty acid oxidation.
What to expect
Liver enzyme improvement by 12-24 weeks.
- Weeks 4-8: Early appetite suppression and weight loss.
- Weeks 12-24: Reduced ALT/AST and liver fat.
- Weeks 24-48: NASH resolution and fibrosis reduction.
Good to know
- Start at lowest dose (0.25mg)
- Slow titration
Staying safe
- Nausea
- Vomiting
- Diarrhea
Avoid if you have:
- Medullary thyroid carcinoma history
- MEN-2
Mechanism of action
Semaglutide reduces liver fat by suppressing appetite, improving insulin sensitivity, and directly reducing de novo lipogenesis in hepatocytes.
Activates GLP-1 receptors on hepatocytes, reducing lipogenesis and increasing fatty acid oxidation.
Pharmacodynamics
Liver enzyme improvement by 12-24 weeks.
Reduced liver fat, improved liver enzymes, less inflammation.
Timeline
- Weeks 4-8: Early appetite suppression and weight loss.
- Weeks 12-24: Reduced ALT/AST and liver fat.
- Weeks 24-48: NASH resolution and fibrosis reduction.
Comparisons
- Semaglutide — effectiveness High, safety Good, cost $$$, Very Easy to use
- Vitamin E — effectiveness Low, safety Excellent, cost $, Very Easy to use
Adverse effects
Common:
- Nausea
- Vomiting
- Diarrhea
Rare:
- Pancreatitis
- Gallstones
Contraindications & risk mitigation
Contraindicated in:
- Medullary thyroid carcinoma history
- MEN-2
- Start at lowest dose (0.25mg)
- Slow titration
Qué hace
Reducción de la grasa hepática, mejora de las enzimas hepáticas y menor inflamación.
Cómo funciona
La semaglutida actúa como una aspiradora de grasa hepática: elimina la grasa de las células del hígado al mejorar cómo tu cuerpo procesa el azúcar y las grasas.
Activa los receptores GLP-1 en los hepatocitos, reduciendo la lipogénesis y aumentando la oxidación de ácidos grasos.
Qué esperar
Mejora de las enzimas hepáticas en 12-24 semanas.
- Semanas 4-8: Supresión temprana del apetito y pérdida de peso.
- Semanas 12-24: Reducción de ALT/AST y grasa hepática.
- Semanas 24-48: Resolución de la NASH y reducción de la fibrosis.
Bueno saber
- Iniciar con la dosis más baja (0,25 mg)
- Titulación lenta
Manteniéndose seguro
- Náuseas
- Vómitos
- Diarrea
Evitar si tienes:
- Antecedentes de carcinoma medular de tiroides
- MEN-2
Mecanismo de acción
La semaglutida reduce la grasa hepática al suprimir el apetito, mejorar la sensibilidad a la insulina y reducir directamente la lipogénesis de novo en los hepatocitos.
Activa los receptores GLP-1 en los hepatocitos, reduciendo la lipogénesis y aumentando la oxidación de ácidos grasos.
Farmacodinamia
Mejora de las enzimas hepáticas en 12-24 semanas.
Reducción de la grasa hepática, mejora de las enzimas hepáticas y menor inflamación.
Cronología
- Semanas 4-8: Supresión temprana del apetito y pérdida de peso.
- Semanas 12-24: Reducción de ALT/AST y grasa hepática.
- Semanas 24-48: Resolución de la NASH y reducción de la fibrosis.
Comparaciones
- Semaglutida — efectividad Alta, seguridad Buena, costo $$$, Muy fácil de usar
- Vitamina E — efectividad Baja, seguridad Excelente, costo $, Muy fácil de usar
Efectos adversos
Comunes:
- Náuseas
- Vómitos
- Diarrea
Raros:
- Pancreatitis
- Cálculos biliares
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Antecedentes de carcinoma medular de tiroides
- MEN-2
- Iniciar con la dosis más baja (0,25 mg)
- Titulación lenta
Reference data
Specifications
- Route
- Subcutaneous
- Cycle length
- Ongoing
FAQ
Common questions
Is semaglutide FDA-approved for NASH?
Not yet; Phase III trials are ongoing and show positive results.
How much does it reduce liver fat?
Studies show 30-40% reduction in hepatic steatosis by MRI.
What is the evidence level?
This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.
Research
Research & sources
Current evidence for Semaglutide (Liver Health) is rated as Limited human data. Limited human data is available.
- 1. Semaglutide in NASH (2021) — DOI:10.1056/NEJMoa2031482
- 2. Semaglutide in NASH (2021)